Technological Offers

Diagnostic method for patients with rheumatoid arthritis.

Description


Method for diagnosing and classifying the severity of patients with RA using epigenetic markers based on DNA methylation alterations.

Genomic DNA is extracted from the leukocyte layer of a blood sample. The level of genomic DNA methylation is then analyzed using established techniques for this type of quantification.

Medical need

Rheumatoid arthritis (RA) is a chronic disease that causes joint damage, disability, and a poor quality of life.

Early detection of RA is crucial to prevent severe damage and improve patients' quality of life. However, in the early stages, the symptoms can be confused with other diseases, making diagnosis difficult. Although there are biomarkers such as rheumatoid factor and ACPA antibodies, these are not completely accurate.

Prevalence

It affects between 0.5-1% of the pulation.
Spain: 240,000 patients.
20,000 new diagnoses each year.

Market

Global diagnostics market: $2,775.1 million in 2023.
CAGR 5,4%.

Other solutions

Use of other biomarkers:
- Rheumatoid factor
- Antibodies against citrullinated proteins.

Diagnosis


IBIMA Plataforma BIONAND inventors


NATALIA MENA VÁZQUEZ
Research group of IBIMA involved: D-03

ANTONIO FERNÁNDEZ NEBRO
Research group of IBIMA involved: D-03

GRACIA MARÍA MARTÍN NÚÑEZ
Research group of IBIMA involved: D-03

PATRICIA RUIZ LIMÓN
Research group of IBIMA involved: A-02

ISABEL MORENO INDIAS
Research group of IBIMA involved: A-02

SARA MANRIQUE ARIJA
Research group of IBIMA involved: D-03

INMACULADA UREÑA GARNICA
Research group of IBIMA involved: D-03

ARKAITZ MUCIENTES RUIZ
Research group of IBIMA involved: D-03

JOSÉ MANUEL LISBONA MONTAÑEZ
Research group of IBIMA involved: D-03

Contact


Innovation and Technology Transfer Office of IBIMA Plataforma BIONAND

[email protected]